Blog Archives

Gilead Sciences (GILD-NASDAQ, $103.81) Financial Modelling for Zydelig

CLL is diagnosed in roughly 15,700 persons annually in the United States. https://www.lls.org/sites/default/files/file_assets/facts.pdf GILD has announced that the success rate of their drug Zydelig has been so successful that the study data resulted in an unbinding of the placebo control

Posted in Portfolio Model Subscription

The end for the Pharmaceutical Bull Cycle?

The denouement of a sectoral investment trend is characteristically well telegraphed. A cable transmission is received. Typically terse, it notes either the demise of, or the malfeasance by, a much admired and widely held company and is generally read in

Posted in Portfolio Model Subscription

Visa Inc. (V-NYSE, $76) Visa Europe to Soon be Acquired?

A transaction to purchase Visa Europe, mentioned some months ago on this site, looks to be in the latter stages of negotiation. A successful conclusion may be announced as early as the date of the quarterly results. http://finance.yahoo.com/news/european-banks-set-windfall-visa-160050401.html As indicated

Posted in Portfolio Model Subscription

PBF ENERGY INC. (PBF-NYSE, $30.69). A Cyclical Addition at the Pullback.

PBF ENERGY INC. has been added to the Global Portfolio. Shares Outstanding 86 million. Enterprise Value of $3.63 billion. EBITDA forecast for 2015: 850 million 2015 forecast EV/EBITDA ratio: 4.4X. Proforma Shares Outstanding : 96 million. Enterprise Value: 4.70 billion

Posted in Portfolio Model Subscription

PBF Energy Inc. (PBF-NYSE, $30.69). A Potential Move from Small-Cap to Mid-Cap.

PBF Energy Inc. is a pure play on refining in the United States. Two recent acquisitions, one of which is to be funded with a smallish equity component, have been announced in the last three months. The terms of both

Posted in Portfolio Model Subscription
Recent Comments
    Archives